Background: Many mutations that contribute to the pathogenesis of acute myeloid leukemia (AML) are undefined. The relationships between patterns of mutations and epigenetic phenotypes are not yet clear.
Methods: We analyzed the genomes of 200 clinically annotated adult cases of de novo AML, using either whole-genome sequencing (50 cases) or whole-exome sequencing (150 cases), along with RNA and microRNA sequencing and DNA-methylation analysis.
Results: AML genomes have fewer mutations than most other adult cancers, with an average of only 13 mutations found in genes. Of these, an average of 5 are in genes that are recurrently mutated in AML. A total of 23 genes were significantly mutated, and another 237 were mutated in two or more samples. Nearly all samples had at least 1 nonsynonymous mutation in one of nine categories of genes that are almost certainly relevant for pathogenesis, including transcription-factor fusions (18% of cases), the gene encoding nucleophosmin (NPM1) (27%), tumor-suppressor genes (16%), DNA-methylation-related genes (44%), signaling genes (59%), chromatin-modifying genes (30%), myeloid transcription-factor genes (22%), cohesin-complex genes (13%), and spliceosome-complex genes (14%). Patterns of cooperation and mutual exclusivity suggested strong biologic relationships among several of the genes and categories.
Conclusions: We identified at least one potential driver mutation in nearly all AML samples and found that a complex interplay of genetic events contributes to AML pathogenesis in individual patients. The databases from this study are widely available to serve as a foundation for further investigations of AML pathogenesis, classification, and risk stratification. (Funded by the National Institutes of Health.).
Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse.Blood. 2015 Nov 26;126(22):2491-501. doi: 10.1182/blood-2015-05-646240. Epub 2015 Oct 5. Blood. 2015. PMID: 26438511 Free PMC article. Clinical Trial.
Recurring mutations found by sequencing an acute myeloid leukemia genome.N Engl J Med. 2009 Sep 10;361(11):1058-66. doi: 10.1056/NEJMoa0903840. Epub 2009 Aug 5. N Engl J Med. 2009. PMID: 19657110 Free PMC article.
Genomic Classification and Prognosis in Acute Myeloid Leukemia.N Engl J Med. 2016 Jun 9;374(23):2209-2221. doi: 10.1056/NEJMoa1516192. N Engl J Med. 2016. PMID: 27276561 Free PMC article. Clinical Trial.
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?Blood. 2011 Jan 27;117(4):1109-20. doi: 10.1182/blood-2010-08-299990. Epub 2010 Oct 28. Blood. 2011. PMID: 21030560 Review.
Origins of aberrant DNA methylation in acute myeloid leukemia.Leukemia. 2014 Jan;28(1):1-14. doi: 10.1038/leu.2013.242. Epub 2013 Aug 20. Leukemia. 2014. PMID: 23958917 Review.
Cited by 1,492 articles
Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia.Front Cell Dev Biol. 2020 May 8;8:249. doi: 10.3389/fcell.2020.00249. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32457898 Free PMC article. Review.
Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.Leukemia. 2020 May 23:1-16. doi: 10.1038/s41375-020-0878-x. Online ahead of print. Leukemia. 2020. PMID: 32447346 Free PMC article.
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions.Front Oncol. 2020 May 6;10:697. doi: 10.3389/fonc.2020.00697. eCollection 2020. Front Oncol. 2020. PMID: 32435621 Free PMC article. Review.
Elevated TNFRSF4 gene expression is a predictor of poor prognosis in non-M3 acute myeloid leukemia.Cancer Cell Int. 2020 May 4;20:146. doi: 10.1186/s12935-020-01213-y. eCollection 2020. Cancer Cell Int. 2020. PMID: 32390761 Free PMC article.
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results.Blood Adv. 2020 May 12;4(9):1942-1949. doi: 10.1182/bloodadvances.2019001349. Blood Adv. 2020. PMID: 32380535 Free PMC article.
- U24CA143840/CA/NCI NIH HHS/United States
- P01CA101937/CA/NCI NIH HHS/United States
- P30 CA016672/CA/NCI NIH HHS/United States
- U24 CA143882/CA/NCI NIH HHS/United States
- U54 HG003067/HG/NHGRI NIH HHS/United States
- U54HG003273/HG/NHGRI NIH HHS/United States
- U24 CA143835/CA/NCI NIH HHS/United States
- U24 CA143866/CA/NCI NIH HHS/United States
- U24CA143858/CA/NCI NIH HHS/United States
- U24CA143882/CA/NCI NIH HHS/United States
- U24CA144025/CA/NCI NIH HHS/United States
- U54HG003067/HG/NHGRI NIH HHS/United States
- U24 CA143845/CA/NCI NIH HHS/United States
- U24 CA143799/CA/NCI NIH HHS/United States
- U54 HG003273/HG/NHGRI NIH HHS/United States
- R01 HG005690/HG/NHGRI NIH HHS/United States
- U24 CA144025/CA/NCI NIH HHS/United States
- U24CA143883/CA/NCI NIH HHS/United States
- U54HG003079/HG/NHGRI NIH HHS/United States
- U24 CA143840/CA/NCI NIH HHS/United States
- U24 CA143843/CA/NCI NIH HHS/United States
- U24CA143867/CA/NCI NIH HHS/United States
- U24CA143835/CA/NCI NIH HHS/United States
- U24 CA143858/CA/NCI NIH HHS/United States
- P30 CA091842/CA/NCI NIH HHS/United States
- U24CA143843/CA/NCI NIH HHS/United States
- U24 CA143848/CA/NCI NIH HHS/United States
- P01 CA101937/CA/NCI NIH HHS/United States
- U24CA143848/CA/NCI NIH HHS/United States
- U54 HG003079/HG/NHGRI NIH HHS/United States
- U24CA143799/CA/NCI NIH HHS/United States
- U24 CA143883/CA/NCI NIH HHS/United States
- R01 CA162086/CA/NCI NIH HHS/United States
- U24CA143866/CA/NCI NIH HHS/United States
- U24CA143845/CA/NCI NIH HHS/United States
- R01 CA083962/CA/NCI NIH HHS/United States
- U24 CA143867/CA/NCI NIH HHS/United States